Helena Smolak
Reporter, Real-Time EMEA News Desk at The Wall Street Journal
Journalist @WSJ chasing breaking news & hidden stories. Former Investigator @WFP @UN. Alumna @MediaLSE. For tips: [email protected]. Views my own.
Articles
-
1 week ago |
wsj.com | Helena Smolak
Updated May 2, 2025 2:13 am ETGerman chemical giant BASF BAS -1.35%decrease; red down pointing triangle stuck to its outlook after first-quarter results but said it was difficult to assess the impact of tariffs at this point. The company warned of a high level of uncertainty due to volatility stemming from tariff announcements and the unpredictability of further U.S. decisions and potential reactions from trading partners. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.
-
1 week ago |
marketscreener.com | Helena Smolak
German chemical giant BASF stuck to its outlook after first-quarter results but said it was difficult to assess the impact of tariffs at this point. The company warned of a high level of uncertainty due to volatility stemming from tariff announcements and the unpredictability of further U.S. decisions and potential reactions from trading partners. However, BASF said it expected to be insulated from the direct impact of tariffs because it produces the majority of its products locally.
-
1 week ago |
tradingview.com | Helena Smolak
BASF Confirms Outlook After Sales Miss, Profit BeatBASBASF posted lower first-quarter sales that missed analysts' expectations, but higher-than-expected earnings left its full-year outlook unchanged.
-
2 weeks ago |
marketscreener.com | Helena Smolak
By Helena Smolak Novartis is set to buy U.S. biotech Regulus Therapeutics for up to $1.7 billion in a move to boost its renal-disease pipeline. The Swiss pharma giant said Wednesday that it would pay Regulus Therapeutics $0.8 billion, and a potential additional $0.9 billion in milestone payments. Regulus Therapeutics specializes in microRNA technology, which focuses on the kinds and amounts of proteins cell make.
-
2 weeks ago |
wsj.com | Helena Smolak
The British pharmaceutical giant said Wednesday that its first-quarter sales rose to 7.52 billion pounds ($10.08 billion) from 7.36 billion pounds the year prior, beating analysts’ expectations of 7.42 billion pounds. Higher demand for its specialty medicines business offset a decline of Arexvy sales for respiratory syncytial virus and sales of Shingrix for shingles. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8Subscribe NowAlready a subscriber?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 85
- Tweets
- 78
- DMs Open
- No
RT @domchopping: https://t.co/0Udb3AHRBF
I spoke with @Novartis 's CEO about why his appetite for obesity deals isn't over yet - and how the Swiss pharma giant plans to bridge its pipeline gap between 2027 to 2030.
Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s https://t.co/Xrg7IxdeIF
Pharma's bet on #AI to advance drug development seems promising but there are hurdles and the biggest aren't even technological. Technology is not the primary bottleneck preventing faster progress; it’s largely operational and cultural challenges. My latest analysis:
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles https://t.co/0RinbBqGhH